• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MDM2 Gene Record

  • Summary
  • Interactions
  • Claims
  • MDM2 4193 Druggable GenomeClinically Actionable

    Alternate Names:

    4193
    MDM2 PROTO-ONCOGENE
    MDM2
    ACTFS
    HDMX
    hdm2
    164785
    6973
    ENSG00000135679
    OTTHUMG00000142827
    Q00987
    E3 UBIQUITIN-PROTEIN LIGASE MDM2
    MDM2_HUMAN
    UBIQUITIN-PROTEIN LIGASE E3 MDM2 (EC 6.3.2.-) (P53-BINDING PROTEIN MDM2) (ONCOPROTEIN MDM2) (DOUBLE MINUTE 2 PROTEIN) (HDM2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q00987]
    3465
    UBIQUITIN-PROTEIN LIGASE E3 MDM2
    PA30718
    T00176
    MGC5370
    LSKB

    Gene Info:

    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Interpro Short Name Znf_RanBP2
    Human Readable Name DRUGGABLE GENOME
    Uniprot Status Swiss-Prot
    Interpro Name Zinc finger, RanBP2-type
    Interpro Acc IPR001876
    Gene Biotype PROTEIN_CODING
    (13 More Sources)

    Gene Categories: Category Details

    TUMOR SUPPRESSOR
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Yoo et al., 2004, Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha., J. Biol. Chem.
    Clement JA et al., 2008, Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53., Bioorg Med Chem
    Hardcastle IR et al., 2011, Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency., J Med Chem
    Yu S et al., 2009, Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction., J Med Chem
    Ribeiro CJ et al., 2014, Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents., Bioorg Med Chem
    Gomez-Monterrey I et al., 2010, Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators., J Med Chem
    Vassilev LT et al., 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2., Science
    Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.
  • NUTLIN-3   MDM2

    Interaction Score: 13.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21314128 19928922 24268795 21058726 14704432


    Sources:
    DTC PharmGKB

  • LISSOCLINIDINE B   MDM2

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18977148


    Sources:
    DTC

  • DIPLAMINE B   MDM2

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18977148


    Sources:
    DTC

  • MILADEMETAN   MDM2

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • IDASANUTLIN   MDM2

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SERDEMETAN   MDM2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • RO-5045337   MDM2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    OncoKB

  • IPILIMUMAB   MDM2

    Interaction Score: 1.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • CHEMBL1492017   MDM2

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NIVOLUMAB   MDM2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • GAMBOGIC ACID   MDM2

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MANGOSTIN   MDM2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PEMBROLIZUMAB   MDM2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • HELENALIN   MDM2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL35482   MDM2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15385570


    Sources:
    NCI

  • THIRAM   MDM2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000135679

    • Version: 101_38

    Alternate Names:
    MDM2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: Q00987

    • Version: 11-September-2012

    Alternate Names:
    4193 Entrez Gene Id
    MDM2 Uniprot Gene Name
    ENSG00000135679 Ensembl Gene Id

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Interpro Short Name Znf_RanBP2

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000135679

    • Version: 26-July-2011

    Alternate Names:
    MDM2 Display Id
    ENSG00000135679 Ensembl Gene Id
    UBIQUITIN-PROTEIN LIGASE E3 MDM2 (EC 6.3.2.-) (P53-BINDING PROTEIN MDM2) (ONCOPROTEIN MDM2) (DOUBLE MINUTE 2 PROTEIN) (HDM2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q00987] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: MDM2

    • Version: 18-August-2020

    Alternate Names:
    PA30718 PharmGKB ID

    Gene Info:

    Publications:
    Vassilev LT et al., 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2., Science
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J

  • CIViC: MDM2

    • Version: 14-September-2020

    Alternate Names:
    4193 Entrez Gene ID
    3465 CIViC Gene ID

    Gene Info:

    Publications:
    Wagner et al., 2017, Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors., J. Clin. Oncol.
    Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.

  • NCI: MDM2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Secchiero et al., 2007, Antiangiogenic activity of the MDM2 antagonist nutlin-3., Circ. Res.
    Pääjärvi et al., 2005, TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents., Carcinogenesis
    Yoo et al., 2004, Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha., J. Biol. Chem.

  • DTC: MDM2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Gomez-Monterrey I et al., 2010, Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators., J Med Chem
    Hardcastle IR et al., 2011, Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency., J Med Chem
    Ribeiro CJ et al., 2014, Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents., Bioorg Med Chem

  • HingoraniCasas: ENSG00000135679

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000135679 Gene Symbol
    MDM2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • OncoKB: MDM2

    • Version: 23-July-2020

    Alternate Names:
    4193 OncoKB Entrez Id
    hdm2 OncoKB Gene Synonym
    HDMX OncoKB Gene Synonym

    Gene Info:

    Publications:

  • HumanProteinAtlas: MDM2

    • Version: 19.3

    Alternate Names:
    ENSG00000135679 Ensembl Gene ID
    HDM2 Human Protein Atlas Gene Synonym
    MGC5370 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • Tempus: MDM2

    • Version: 11-November-2018

    Alternate Names:
    MDM2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Ubiquitin-protein ligase E3 Mdm2

    • Version: 2020.06.01

    Alternate Names:
    MDM2 TTD Gene Abbreviation
    T00176 TTD Target ID

    Gene Info:

    Publications:

  • MskImpact: MDM2

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: MDM2

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: MDM2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • GO: MDM2

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    TUMOR SUPPRESSOR

    Publications:

  • Oncomine: MDM2

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21